⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

BIIB News

Biogen Inc. Common Stock

TJ Biopharma Doses First Patient in Phase 1 Trial of TJ-C64B, a CLDN6x4-1BB Bispecific Antibody for CLDN6-Positive Solid Tumors